Phase 2, dose-ranging study of vupanorsen in patients with diabetes, hepatic steatosis and hypertriglyceridaemia (NCT03371355)

Educational partners and supporters (others pending)

Amarin Logo
Ionis Logo
Kowa Logo
Pfizer Logo